Shyra Gardai, Ph.D.

Chief Scientific Officer

Shyra Gardai is the Chief Scientific Officer at EpiBiologics. Shyra brings over 20 years of experience as an executive manager leading innovative discovery research groups focused on turning novel ideas into clinical stage therapies to battle cancer, autoimmune, and neurodegenerative diseases. During her time at Elan Pharmaceuticals and Seattle Genetics, Shyra oversaw the selection and advancement of 6 therapeutic candidates that integrated novel antibody, chemistry and protein engineering technologies into Phase 1 clinical studies. Most recently Shyra was the Vice President of Therapeutic Discovery Research at Seattle Genetics where she led a 60+ member team comprised of chemists, protein engineers, immunologists and cancer biologists focused on discovering new treatments for cancer patients. Shyra trained as an immunologist and obtained her Ph.D. at the University of Colorado and completed a postdoctoral research fellowship in the Department of Immunology at National Jewish Health.